New radiopharmaceuticals for cancer imaging and biological characterization using PET

International Congress Series

Volumn 1264, Issue C, 2004, Pages 158-165

  Fukuda, Hiroshi ^a   Furumoto, Shozo ^a   Iwata, Ren ^a   Kubota, Kazuo ^b  

^a TOHOKU UNIVERSITY   (Japan)

^b NATIONAL CENTER FOR GLOBAL HEALTH AND MEDICINE   (Japan)

Author keywords

Matrix metalloproteinase; Oncology; PET; Tyrosine

Indexed keywords

EID: 53549125702     PISSN: 05315131     EISSN: None     Source Type: Book Series    
DOI: 10.1016/j.ics.2004.01.007     Document Type: Article

References (15)

1. Gambihir, S.S., Crernin, J., Schwinner, J., et al. A tabulated summary of the FDG PET literature. J. Nucl. Med. 42 (2001), 1s–93s.
2. Kubota, K., From tumor biology to clinical PET: a review of positron emission tomography (PET) in oncology. Ann. Nucl. Med. 15 (2001), 471–486.
3. Laverman, P., Boerman, O.C., Corstens, F.H.M., Oyen, W.J.G., Fluorinated amino acids for tumor imaging with positron emission tomography. Eur. J. Nucl. Med. 29 (2002), 681–690.
4. Wester, H.J., Herz, M., Weber, W., et al. Synthesis and radiopharmacology of O-(2-[18F]fluoroethyl)-L-tyrosine for tumor imaging. J. Nucl. Med. 40 (1999), 205–212.
5. Tang, G.H., Wang, M.F., Tang, X.L., Luo, L., Gan, M.Q., Synthesis and evaluation of O-(3-[F-18] fluoropropyl)-L-tyrosine as an oncologic PET tracer. Nucl. Med. Biol. 30 (2003), 733–739.
6. Iwata, R., Furumoto, S., Pascali, C., et al. Radiosynthesis of O-[C-11]methyl-L-tyrosine and O-[F-18]fluoromethyl-L-tyrosine as potential PET tracers for imaging amino acid transport. Appl. Radiat. Isotopes 57 (2002), 347–352.
7. Iwata, R., Pascali, C., Bongi, A., Furumoto, S., et al. [F-18]Fluoromethyl triflate, a novel and reactive [F-18]fluoromethylating agent: preparation and application to the on-column preparation of [F-18]fluorocholine. Appl. Radiat. Isotopes 57 (2002), 347–352.
8. Cawston, T.E., Matrix metalloproteinase inhibitors and the prevention of connective tissue breakdown. Pharmacol. Ther. 70 (1996), 163–182.
9. Hiraoka, N., Allen, E., Apel, I.J., et al. Matrix metalloproteinases regulate neovascularization by acting as pericellular fibrinolysins. Cell 95 (1998), 365–377.
10. Liotta, L.A., Tryggvaason, K., Garbisa, S., et al. Metastatic potential correlates with enzymatic degradation of basement membrane collagen. Nature 284 (1980), 67–68.
11. Whittaker, M., Floyd, C.D., Brown, P., Gearing, A.J.H., Design and therapeutic application of matrix metalloproteinase inhibitors. Chem. Rev. 99 (1999), 2735–2776.
12. Tamura, Y., Watanabe, F., Nakatani, T., et al. Highly selective and orally active inhibitors of type iv collagenase (mmp-9 and mmp-2)-n-sulfonylamino acid derivatives. J. Med. Chem. 41 (1998), 640–649.
13. Gatto, C., Rieppi, M., Borsotti, P., et al. BAY 12-9566, a novel inhibitor of matrix metalloproteinases with antiangiogenic activity. Clin. Cancer Res. 5 (1999), 3603–3607.
14. Furumoto, S., Iwata, R., Ido, T., Design and synthesis of fluorine-18 labeled matrix metalloproteinase inhibitors for cancer imaging. J. Labelled Compd Radiopharm. 45 (2002), 975–986.
15. 18F-labeled matrix metalloproteinase-2 inhibitor. Nucl. Med. Biol. 30 (2003), 119–125.